A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient Mice

Cell

Volumn 85, Issue 5, 1996, Pages 733-744

  Fero, Matthew L ^a   Rivkin, Michael ^b   Tasch, Michael ^c   Porter, Peggy ^a   Carow, Catherine E ^c   Firpo, Eduardo ^a   Polyak, Kornelia ^d   Tsai, Li Huei ^b   Broudy, Virginia ^c   Perlmutter, Roger M ^c   Kaushansky, Kenneth ^c   Roberts, James M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MURINAE;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; ENZYME INACTIVATION; FEMALE STERILITY; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; GENE TARGETING; GIGANTISM; HEMATOPOIETIC CELL; HYPERPLASIA; HYPOPHYSIS INTERMEDIATE LOBE; MOUSE; NONHUMAN; OVARY FOLLICLE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SYNDROME;

ADENOMA; ANIMALS; BASE SEQUENCE; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DNA PRIMERS; ENZYME INHIBITORS; FEMALE; GENE TARGETING; GIGANTISM; HYPERPLASIA; INFERTILITY, FEMALE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; PITUITARY NEOPLASMS; SYNDROME; T-LYMPHOCYTES; THYMUS HYPERPLASIA; TUMOR SUPPRESSOR PROTEINS;

EID: 15844384256     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)81239-8     Document Type: Article

References (59)

1. fyn. Cell 70, 751-763.
2. Broudy, V.C., Tait, J.F., and Powell, J.S. (1988). Recombinant human erythropoietin: purification and analysis of carbohydrate linkage. Arch. Biochem. Biophys. 265, 329-336.
3. Broudy, V.C., Lin, N.L., and Kaushansky, K. (1995). Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85, 1719-1726.
4. Brugarolas, J., Chandrasekaran, C., Gordon, J., Beach, D., Jacks, T., and Hannon, G. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557.
5. 3H]thymidine uptake measurement. Endocrinology 12, 1201-1211.
6. Kip1 for restriction point control of thefibroblast cell cycle. Science, in press.
7. Cooke, M.P., Abraham, K.M., Forbush, K.A., and Perlmutter, R.M. (1991). Regulation of T cell receptor signaling by asrc family protein-tyrosine kinase (p59fyn). Cell 65, 281-291.
8. Cross, F. (1988). DAF1, a mutant gene affecting size control, pheromone arrest, and cell cycle kinetics of Saccharomyces cerevisiae. Mol. Cell. Biol. 8, 4675-4684.
9. DeChiara, T., Efstratiadis, A., and Robertson, E. (1990). A growth deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345, 78-80.
10. CIP1/WAF1 undergo normal development but are defective in G1 checkpoint control. Cell 82, 675-684.
11. El-Diery, W., Tokino, T., Velculescu, V., Levy, D., Parsons, R., Trent, J., Lin, D., Mercer, E., Kinzler, K., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
12. Firpo, E., Koff, A., Solomon, M., and Roberts, J. (1994). Inactivation of a Cdk2 inhibitor during IL-2 induced proliferation of human T-lymphocytes. Mol. Cell. Biol. 14, 4889-4901.
13. Flores-Rozas, H., Kelman, Z., Dean, F., Pan, Z., Harper, J.W., Elledge, S., O'Donnell, M., and Hurwitz, J. (1994). CDK-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA relication catalyzed by the DNA polymerase and holoenzyme. Proc. Natl. Acad. Sci. USA 91, 8655-8659.
14. Gary, K., and Chronwall, B. (1992). The onset of dopaminergic innervation during ontogeny decreases melanotrope proliferation in the intermediate lobe of the rat pituitary. Int. J. Dev. Neurosci. 10, 131-142.
15. Gehlert, D., Bishop, J., Schafer, M., and Chronwall, B. (1988). Rat intermediate lobe in culture: dopaminergic regulation of POMC biosynthesis and cell proliferation. Peptides 9(Suppl. 1), 161-168.
16. Gerdes, J., Becker, M., and Key, G. (1992). Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J. Pathol. 168, 85-86.
17. Gu, Y., Turek, C., and Morgan, D. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707-710.
18. Halevy, O., Novitch, B., Spicer, D., Skapek, S., Rhee, J., Hannon, G., Beach, D., and Lasser, A. (1995). Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267, 1018-1021.
19. Harper, J.W., Adami, G., Wei, N., Keyomarse, K., and Elledge, S. (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
20. Hsu, S., and Soban, E. (1982). Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J. Histochem. Cytochem. 30, 1079-1082.
21. Hsu, S., Raine, L., and Fanger, H. (1981). Use of biotin-avidin-peroxidase conplex (ABC) in immuno peroxidase techniques: a comparison between ABC and unlabeled antibody techniques. Am. J. Clin. Pathol. 75, 816-821.
22. Hu, N., Gutsmann, A., Herbert, D.C., Bradley, A., Lee, W.H., and Lee, E.Y. (1994). Heterozygous Rb-1 δ 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9, 1021-1027.
23. Kip1) of cyclin-dependent kinase 4 activation. Cell 79, 487-496.
24. Kaushansky, K., Lok, S., Holly, R.D., Broudy, V.C., Lin, N., Bailey, M.C., Forstrom, J.W., Buddle, M.M., Oort, P.J., Hagen, F.S., et al. (1994). Promotion of megakaryocyte progenitor expansion and differentiation by the C-Mpl ligand thrombopoietin. Nature 369, 568-571.
25. Kawamata, N., Morosetti, R., Miller, S., Park, D., Spirin, K., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilcyznski, S., et al. (1995). Molecular analysis of the cyclin dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55, 2266-2269.
26. Koff, A., Ohtsuki, M., Polyak, K., Roberts, J., and Massague, J. (1993). Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260, 536-539.
27. Kogan, S.C., Doherty, M., and Gitschier, J. (1987). An improved method for prenatal diagnosis of genetic diseases by analysis of amplified DNA sequences. N. Engl. J. Med. 317, 985-990.
28. Kip2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9, 639-649.
29. Luo, Y., Hurwitz, J., and Massague, J. (1995). Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 Cip1. Nature 375, 159-161.
30. Mathews, L., Hammer, R., Behringer, R., D'Ercole, A.J., Bell, G., Brinster, R., and Palmiter, R. (1988). Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 123, 2827-2833.
31. Cip1 cdk inhibitor family is a candidate tumor suppressor gene. Genes Dev. 9, 650-662.
32. Noda, A., Ning, Y., Venable, S., Pereira-Smith, O., and Smith, J. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211, 90-98.
33. Kip1 cyclin-Cdk kinase inhibitor prevented by rapamycin. Nature 372, 570-573.
34. Ohtsubo, M., and Roberts, J. (1993). Cyclin dependent regulation of G1 in mammalian fibroblasts. Science 259, 1908.
35. Palmiter, R., Brinster, R., Hammer, R., Trumbauer, M., Rosenfeld, M., Birnberg, N., and Evans, R. (1982). Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 300, 611-615.
36. Palmiter, R., Nordstedt, G., Gelinas, R., Hammer, R., and Brinster, R. (1983). Metallothionein-human growth hormone fusion genes stimulate growth of mice. Science 222, 809-814.
37. Cip1 in muscle and other terminally differentiating cells. Science 267, 1024-1027.
38. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55, 1206-1210.
39. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8, 9-22.
40. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66.
41. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 55, 1211-1214.
42. Quaife, C., Mathews, L., Pinkert, C., Hanner, R., Brinster, R., and Palmiter, R. (1989). Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124, 40-48.
43. Quelle, D., Ashmun, R., Shurtleff, S., Kato, J.Y., Bar-Sagi, D., Roussel, M., and Sherr, C.J. (1993). Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7, 1559-1571.
44. Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9, 1831-1845
45. Roberts, J.M., Koff, A., Polyak, K., Firpo, E., Collins, S., Ohtsubo, M., and Massague, J. (1994). Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harbor Symp. Quant. Biol. 59, 31-38.
46. Sato, Y., Suto, Y., Pietenpol, J., Golub, T., Gilliland, G., Davis, E., Le Beau, M., Roberts, J., Vogelstein, B., Rowley, J., and Bohlander, S. (1995). TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 86, 1525-1533.
47. Serrano, M., Hannon, G., and Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ CDK4. Nature 366, 704-707.
48. Sherr, C., and Roberts, J. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
49. Slingerland, J., Hengst, L., Pan, C., Alexander, D., Stampfer, M., and Reed, S. (1994). A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol.Cell. Biol. 14, 3683-3694.
50. Soriano, P., Montgomery, C., Geske, R., and Bradley, A. (1991). Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702.
51. Toyoshima, H., and Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67-74.
52. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163.
53. van Buul-Offers, S., Haan, K., Reijnen-Gresnigt, M., Meinsma, D., Jansen, M., Oei, S., Bonte, E., Sussenbach, J., and Van den Brande, J. (1995). Overexpression of human insulin-like growth factor II in transgenic mice causes increased growth of the thymus. J. Endocrinol. 144, 491-502.
54. Waga, S., Hannon, G., Beach, D., and Stillman, B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369, 574-578.
55. Ward, A., Bates, P., Fisher, R., Richardson, L., and Graham, C. (1994). Disproportionate growth in mice with lgf-2 transgenes. Proc. Natl. Acad. Sci. USA 91, 10365-10369.
56. Williams, B.O., Schmitt, E.M., Remington, L., Bronson, R.T., Albert, D.M., Weinberg, R.A., and Jacks, T. (1994). Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13, 4251-4259.
57. Wolf, E., Kramer, R., Blum, W., Foll, J., and Brem, G. (1994). Consequences of postnatally elevated insulin-like growth factor II in transgenic mice: endocrine changes and effects on body and organ growth. Endocrinology 135, 1877-1886.
58. Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993a). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
59. Xiong, Y., Zhang, H., and Beach, D. (1993b). Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev. 7, 1572-1583.